Moderna Past Earnings Performance

Past criteria checks 0/6

Moderna's earnings have been declining at an average annual rate of -10.9%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 23.3% per year.

Key information

-10.9%

Earnings growth rate

-10.9%

EPS growth rate

Biotechs Industry Growth36.3%
Revenue growth rate23.3%
Return on equity-18.6%
Net Margin-43.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Moderna makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BASE:MRNA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,081-2,2241,2930
30 Jun 245,050-5,8671,4540
31 Mar 245,153-5,9681,5180
31 Dec 236,848-4,7141,5490
30 Sep 239,121-3,4661,4540
30 Jun 2310,6541,2071,2900
31 Mar 2315,0594,7841,1690
31 Dec 2219,2638,3621,1320
30 Sep 2221,39011,7659580
30 Jun 2222,99514,0558480
31 Mar 2222,60014,6387580
31 Dec 2118,47112,2025670
30 Sep 2111,8317,0614450
30 Jun 217,0193,4953250
31 Mar 212,7325982410
31 Dec 20803-7471880
30 Sep 20246-5971350
30 Jun 20106-4881150
31 Mar 2052-5051060
31 Dec 1960-5141100
30 Sep 1982-5351220
30 Jun 19106-4991120
31 Mar 19122-4591050
31 Dec 18135-402940
30 Sep 18192-299720
30 Jun 18192-280700
31 Mar 18199-266650
31 Dec 17206-270650
31 Dec 16108-230570

Quality Earnings: MRNA is currently unprofitable.

Growing Profit Margin: MRNA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MRNA is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare MRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: MRNA has a negative Return on Equity (-18.65%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 19:23
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Moderna, Inc. is covered by 42 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Ishan MajumdarBaptista Research
Huidong WangBarclays